In the 6th part of the SPM interview series, Charles Serhan, PhD, DSc provides insights into the query: “What role do you envision lipid mediators and active resolution will play in future clinical decision-making?” Dr. Serhan shares an edifying history on resolvins, from molecular work following their discovery in 2000, to the growing body of in vivo animal model results in inflammatory and infection processes, and now to the ongoing human clinical studies.
Charles Serhan, PhD, DSc is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital and Professor of Anesthesia at Harvard Medical School.
